Summary
Chugai Pharmaceutical Co Ltd (Chugai) is a subsidiary of Hoffmann-La Roche Ltd which focus on the manufacturing marketing, import and export of new pharmaceutical products. The company's product portfolio focuses on various therapeutic areas including cancer treatment; bone and joint diseases; renal diseases; transplant, immunology and infectious diseases and others. Chugai's products include Avastin, Herceptin, Rituxan, Xeloda, Neutrogin, Tarceva, and Kytril for cancer treatements; Evista, Actemra, Suvenyl, Alfarol, Edirol for in bone and joint diseases; and Epogin, Mircera, Oxarol for renal diseases. Under its transplant, immunological infectious diseases area it markets and distributes Pegasys, Copegus and CellCept. Other products offered by the company include Sigmart, Tamiflu and others. The company also markets its pharmaceutical products in overseas markets, such as the US, the UK, Germany, France, Taiwan, China and Korea. Chugai is headquartered at Chuo-ku in Tokyo, Japan.
Chugai Pharmaceutical Co Ltd (4519) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Chugai Pharmaceutical Co Ltd, Medical Devices Deals, 2011 to YTD 2017 11
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 15
Partnerships 15
Helsinn Enters into Licensing Agreement with Chugai Pharma for Netupitant-Palonosetron Fixed-Dose Combination 15
Astellas Pharm, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharma and Chugai Pharma to Enter into Agreemet with Four Research Institutions 15
Chugai Pharmaceutical Enters into Agreement with Osaka University 17
Chugai Pharma Enters Into Co-Development Agreement With Nippon Shinyaku For GA101 18
Schnell BioPharma Enters Into Co-Development Agreement With Aprogen And Chunggei Pharm 19
Licensing Agreements 20
Chugai Pharma Enters into Licensing Agreement with Pharma Mar 20
Berlin-Chemie Enters into Licensing Agreement with Chugai Pharma 21
Maruho Enters into Licensing Agreement with Chugai Pharma 22
Galderma Pharma to Enter into Licensing Agreement with Chugai Pharma 23
Roche Enters into Licensing Agreement with Chugai Pharma for Recycling Antibody SA237 24
Chugai Pharma Enters into Licensing Agreement with Two Cells 24
BioMarin Pharma Enters into Sub-license Agreement with Chugai Pharma 25
Kowa Company Enters into Licensing Agreement with Chugai Pharmaceutical 26
EpiVax Enters into Licensing Agreement with Chugai Pharma 27
Roche Amends Licensing Agreement with Chugai Pharma 28
PharmaMar Enters into Licensing Agreement with Chugai Pharma for Aplidin 29
Chugai Pharma Enters into Licensing Agreement with Roche 29
Helsinn Enters Into Licensing Agreement With Chugai Pharma Marketing For Anamorelin 30
Chugai Pharma Enters Into Licensing Agreement With Debiopharm Group For FF284 31
Chugai Pharma Expands Licensing Agreement with Kowa for DEBERZA 32
Chugai Pharma Extends Licensing Agreement With Genedata For Genedata Expressionist Software 33
Chugai Pharma Enters Into Licensing Agreement With Roche For MetMAb And Lebrikizumab 34
Chugai Pharma Enters Into Licensing Agreement With Roche For Vemurafenib 35
Asset Transactions 36
Eisai Acquires Rights to Manufacture Active Pharmaceutical Ingredients in Japan from Chugai Pharma and F. Hoffman-La Roche 36
Acquisition 38
Roche May Acquire 40% Stake in Chugai Pharma 38
Chugai Pharmaceutical Co Ltd - Key Competitors 39
Key Employees 40
Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Appendix 45
Methodology 45
About GlobalData 45
Contact Us 45
Disclaimer 45List of Tables
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 1
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Chugai Pharmaceutical Co Ltd, Deals By Therapy Area, 2011 to YTD 2017 9
Chugai Pharmaceutical Co Ltd, Medical Devices Deals, 2011 to YTD 2017 11
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Helsinn Enters into Licensing Agreement with Chugai Pharma for Netupitant-Palonosetron Fixed-Dose Combination 15
Astellas Pharm, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharma and Chugai Pharma to Enter into Agreemet with Four Research Institutions 15
Chugai Pharmaceutical Enters into Agreement with Osaka University 17
Chugai Pharma Enters Into Co-Development Agreement With Nippon Shinyaku For GA101 18
Schnell BioPharma Enters Into Co-Development Agreement With Aprogen And Chunggei Pharm 19
Chugai Pharma Enters into Licensing Agreement with Pharma Mar 20
Berlin-Chemie Enters into Licensing Agreement with Chugai Pharma 21
Maruho Enters into Licensing Agreement with Chugai Pharma 22
Galderma Pharma to Enter into Licensing Agreement with Chugai Pharma 23
Roche Enters into Licensing Agreement with Chugai Pharma for Recycling Antibody SA237 24
Chugai Pharma Enters into Licensing Agreement with Two Cells 24
BioMarin Pharma Enters into Sub-license Agreement with Chugai Pharma 25
Kowa Company Enters into Licensing Agreement with Chugai Pharmaceutical 26
EpiVax Enters into Licensing Agreement with Chugai Pharma 27
Roche Amends Licensing Agreement with Chugai Pharma 28
PharmaMar Enters into Licensing Agreement with Chugai Pharma for Aplidin 29
Chugai Pharma Enters into Licensing Agreement with Roche 29
Helsinn Enters Into Licensing Agreement With Chugai Pharma Marketing For Anamorelin 30
Chugai Pharma Enters Into Licensing Agreement With Debiopharm Group For FF284 31
Chugai Pharma Expands Licensing Agreement with Kowa for DEBERZA 32
Chugai Pharma Extends Licensing Agreement With Genedata For Genedata Expressionist Software 33
Chugai Pharma Enters Into Licensing Agreement With Roche For MetMAb And Lebrikizumab 34
Chugai Pharma Enters Into Licensing Agreement With Roche For Vemurafenib 35
Eisai Acquires Rights to Manufacture Active Pharmaceutical Ingredients in Japan from Chugai Pharma and F. Hoffman-La Roche 36
Roche May Acquire 40% Stake in Chugai Pharma 38
Chugai Pharmaceutical Co Ltd, Key Competitors 39
Chugai Pharmaceutical Co Ltd, Key Employees 40
Chugai Pharmaceutical Co Ltd, Other Locations 42
Chugai Pharmaceutical Co Ltd, Subsidiaries 43List of Figures
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Chugai Pharmaceutical Co Ltd, Medical Devices Deals, 2011 to YTD 2017 11
